OMERS ADMINISTRATION Corp Acquires Shares of 21,800 Immunocore Holdings PLC Sponsored ADR $IMCR

OMERS ADMINISTRATION Corp bought a new position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 21,800 shares of the company’s stock, valued at approximately $684,000.

A number of other hedge funds have also modified their holdings of IMCR. Caitong International Asset Management Co. Ltd boosted its position in Immunocore by 4,696.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after acquiring an additional 1,268 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new position in Immunocore in the 2nd quarter worth approximately $42,000. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Immunocore during the 2nd quarter worth approximately $248,000. Lido Advisors LLC purchased a new stake in shares of Immunocore in the second quarter valued at approximately $255,000. Finally, Checkpoint Capital L.P. acquired a new stake in shares of Immunocore in the first quarter valued at approximately $267,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Trading Up 4.7%

NASDAQ IMCR opened at $37.88 on Thursday. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. The stock has a market capitalization of $1.91 billion, a P/E ratio of -66.46 and a beta of 0.77. The firm’s 50-day moving average is $34.93 and its two-hundred day moving average is $34.19. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $40.53.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.32. Immunocore had a negative net margin of 7.70% and a negative return on equity of 7.67%. The business had revenue of $103.69 million during the quarter, compared to analysts’ expectations of $137.29 million. During the same period last year, the business earned $0.17 earnings per share. The business’s revenue for the quarter was up 29.2% on a year-over-year basis. On average, sell-side analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Wells Fargo & Company began coverage on Immunocore in a research note on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday, October 22nd. Guggenheim started coverage on shares of Immunocore in a report on Thursday, September 18th. They issued a “neutral” rating on the stock. Finally, Wall Street Zen upgraded shares of Immunocore from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.00.

Insider Buying and Selling

In other news, insider David M. Berman sold 22,532 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $35.67, for a total transaction of $803,716.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.40% of the stock is owned by company insiders.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.